| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will release earnings results for the third quarter, before the opening bell on Monday, Nov. 3.
Analysts expect the Westbrook, Maine-based company to report quarterly earnings at $3.13 per share, up from $2.80 per share in the year-ago period. The consensus estimate for IDEXX Laboratories' quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier, according to data from Benzinga Pro.
On Aug. 4, IDEXX Laboratories reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates.
Shares of IDEXX Laboratories rose 0.2% to close at $629.51 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
Considering buying IDXX stock? Here’s what analysts think:

Read This Next:
Photo via Shutterstock
Posted In: IDXX